Rethinking Blood Safety for Thalassemia Patients in India

Every child with thalassemia major needs a blood transfusion every 15–20 days. That adds up to around 18–20 transfusions a year and 500–700 transfusions over a lifetime. 50% of them lose life within 25 years of birth due several complications. These transfusions are life-saving, but they also carry risks such as HIV, Hepatitis B, and Hepatitis C.

Globally, Nucleic Acid Testing (NAT) is considered the gold standard in blood safety because it reduces the “window period” for detecting infections. NAT can detect:

• HIV in 9–11 days (vs 22 days by serology),
• Hepatitis B in 20–25 days (vs 59 days),
• Hepatitis C in 10–12 days (vs 70 days).

But in India, the real question is: does NAT make sense for us?

One large Indian study screened 48,762 blood donations with NAT. It picked up 43 Hepatitis B cases that standard serology missed — that’s about 1 in 1,134 donations. But there were no additional detections for HIV or Hepatitis C. The cost of testing was ₹5.85 crore. In health terms, the study calculated a gain of only 1.38 quality-adjusted life years (QALYs), making the cost per QALY ₹3.64 crore — about 274 times higher than India’s per capita income. In simple terms: NAT worked, but it was not cost-effective in the Indian setting.

Another systematic review reached a similar conclusion — while NAT reduces residual risk, its high cost and operational burden make it impractical for routine use in developing countries.

As a primary research, we reviewed 18 deaths among thalassemia patients in our network. The causes were telling:

• Around 50% were due to thalassemia complications such as iron overload and failed bone marrow transplants.
• Several deaths involved HIV or Hepatitis infections, pointing to unsafe transfusions.
• At least 20% were preventable, caused by hospital-acquired infections, steroid misuse, or poor post-surgical care.

This reflects what national data already shows: with 1.5 million transfusions happening every year in India, even a small risk translates into a significant health burden for transfusion-dependent patients.

If universal NAT is too costly, India can still achieve safer transfusions through more sustainable steps:

• Strengthening serology: ELISA and CLIA-based testing costs about ₹200–300 per unit, compared to ₹1,000+ for NAT, and is already scalable across blood banks.
• Universal Hepatitis B vaccination: At less than ₹100 per dose, it prevents lifelong infection and is proven to be one of the most cost-effective public health interventions.
• Voluntary, repeat donors: Data shows that repeat donors have significantly lower infection risk compared to first-time or replacement donors.
• Carrier screening (HPLC): With a cost of ₹500–800 per test, this can identify carriers early, reducing new thalassemia births so that the requirement for blood transfusion itself goes down.
• Early HSCT (bone marrow transplant): Though expensive upfront (₹20–30 lakh), it can eliminate lifelong transfusion needs, which otherwise cost ₹2–5 lakh per year per patient on the healthcare system.

For patients who need regular transfusions, like those with thalassemia, our Blood Bridge model shows how community solutions can be transformational.

• Each patient is supported by 8–10 committed donors, donating in rotation every 3–4 months.
• This ensures predictable access to blood, avoiding the last-minute scramble.
• By depending on repeat voluntary donors, the risk of TTIs is reduced compared to crisis-based donations.

This model does not replace medical testing — but it creates a circle of safety and reliability that reduces dependence on high-risk, unvetted donations.

With this approach, India doesn’t need to replicate the models of high-income countries as one size wouldn't fit all. We need solutions that balance safety, cost, and practicality. A realistic path forward could be:

• Stronger and universal serology testing,
• Scaling up Hepatitis B vaccination,
• Promoting voluntary, repeat donor systems,
• Expanding carrier screening,
• And building structured ecosystems like Blood Bridge for patients with regular transfusion needs.

Because no child should ever contract an infection from the very blood that is meant to save their life.

At Blood Warriors, we continue to dream of an India where no child is born with thalassemia by 2035 — and until then, every transfusion is safe, reliable, and filled with dignity.

#Thalassemia #BloodSafety #HealthcareIndia #BloodDonation #BloodBridge